Montelukast sodium combined with fluticasone propionate for children with cough variant asthma

Abstract

Objective To investigate the efficacy and safety of montelukast sodium combined with fluticasone propionate in treatment of children with cough variant asthma. Methods Two hundred and forty children diagnosed as cough variant asthma in our hospital during February 2013 to January 2015 were randomized into three groups.Children in group Mon+ Flu were given montelukast sodium combined with inhaled fluticasone propionate, children in group Flu was given inhaled corticosteroids alone and children in group Mon was given montelukast sodium alone.Cough, lung function and adverse reactions were observed after 8 and 12 weeks of treatment and the recurrences of cough symptoms were followed up within 24 weeks. Results After 8 weeks of treatment, the score of cough in group Mon+ Flu (1.1±0.7) was lower than those in groups Flu (1.7±0.8) and Mon (1.6±0.8) (t=4.973, 4.353, P 0.05). Meantime, the percentage of predicted in FEV1 in group Mon+ Flu (93.4±15.8) was significantly higher than those in group Flu (87.4±11.0) and group Mon (86.5±9.8)(t=2.804, 3.315, P 0.05). After 12 weeks of treatment, there was no significant difference in scores of cough and percentage of predicted in FEV1 and PEF among three groups (P>0.05). There was no significant difference in incidence of adverse reactions among three groups (χ2=1.026, P>0.05). The recurrence rate of group Mon+ Flu (3.85%) and group Flu(5.26%) were significantly lower than that of group Mon(17.33%)(χ2=7.428, 5.505, P 0.05). Conclusions For children with cough variant asthma montelukast sodium combined with fluticasone propionate has better efficacy than monotherapy in 8 weeks of treatment, but there was no difference in 12 weeks of treatment.The recurrence rate in group Mon+ Flu and group Flu is lower than that in group Mon. Key words: Child; Treatment outcome; Cough variant asthma